Navigation Links
Physicians Hail VNUS Device for Closing Diseased Perforating Veins
Date:11/1/2007

ClosureRFS Stylet 'Ideal' for Treating Condition Affecting Four Million

Americans

SAN JOSE, Calif., Nov. 1 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. (Nasdaq: VNUS), a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease, today announced the widespread success and rapid market growth of the VNUS ClosureRFS(TM) Stylet, an endovenous radiofrequency (RF) ablation catheter currently employed by more than 500 physicians to treat a specific varicose vein-related condition in the lower leg. The ClosureRFS Stylet is the only endovascular ablation device specifically cleared by the FDA for the treatment of incompetent perforating veins or IPVs, which can produce calf and ankle swelling and skin ulcerations in about four million Americans. Over 15,000 minimally invasive ClosureRFS procedures have been performed worldwide to heat and close diseased perforators.

"I have performed over 700 procedures with the ClosureRFS Stylet, and I consider it a giant step forward in our treatment of severe venous insufficiency," said Dr. Charles J. Rodman, MD., of Beaumont, Texas. "Our patients are primarily those with advanced venous disease, and they almost always present with large, incompetent perforating veins that unquestionably must be addressed in the course of treatment. The RFS Stylet is simple to use and small enough to handle with precision, and among physicians like myself treating this patient population, I believe there's uniform agreement that it's the best device available."

"ClosureRFS is absolutely the best way of closing perforators, with none of the drawbacks of other techniques we have researched," said Dr. Mark Whiteley, vascular surgeon and director of The Whiteley Clinic in Surrey, England. "The beauty of the RFS Stylet is that the ultrasound lets you know exactly where you are at all times during the procedure, so it reduces or eliminates the risk of complications, and you're certain of getting successful ablation of the vein exactly at the point you want it. Perforator incompetence has proven to be a common cause of varicose vein recurrence, even in patients whose truncal reflux disease has been successfully treated, so we know that where the condition exists, it must be treated -- and ClosureRFS is clearly the device of choice."

"In order to provide total vein care for venous insufficiency, I think it's vital to address perforating veins as well as the saphenous vein, because almost all of the leg ulcers and post-treatment recurrences we see are associated with diseased perforators," said Thomas Pester, MD., of El Paso, Texas. "The ClosureRFS Stylet is an ideal device for dealing with this issue -- it's very easy to use, the results are quite good and the patients are comfortable with it. I would recommend it to every physician treating patients with venous reflux disease."

ClosureRFS can be performed either as a primary outpatient procedure or as an adjunct to saphenous vein ablation procedures. VNUS has launched an improved version of the ClosureRFS Stylet, which now includes an integrated cable and a new streamlined hub designed for easier use and better ergonomics. For physicians seeking to treat the whole spectrum of venous pathology in managing patients with venous disease, the improved ClosureRFS Stylet is the only endovascular ablation device specifically cleared by the FDA for the treatment of incompetent perforator veins.

"The ClosureRFS Stylet has proven itself as a vital tool for physicians treating the perforator incompetence often seen in patients with advanced venous disease, and we're pleased with how quickly and enthusiastically it has been adopted by the medical community," said Brian E. Farley, President and CEO of VNUS. "This latest version of the RFS Stylet represents a major step forward, particularly in ease of use for physicians, and it addresses a rapidly growing market for the treatment of this form of venous insufficiency."

ABOUT VNUS MEDICAL TECHNOLOGIES, INC.

Founded in 1995 and headquartered in San Jose, California, VNUS Medical Technologies (Nasdaq: VNUS) is a worldwide leader in medical devices for the minimally invasive treatment of venous reflux disease, a progressive condition that causes the varicose veins afflicting 25 million Americans. The pioneering company in the field, VNUS now offers the ClosureFAST system, which consists of a proprietary radiofrequency (RF) generator and proprietary disposable endovenous catheters and devices to close diseased veins through the application of temperature-controlled RF energy. VNUS devices have been used in more than 250,000 procedures worldwide. For more information, please visit http://www.vnus.com.


'/>"/>
SOURCE VNUS Medical Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Startling Expose – Physicians Often Have No Regular Source Of Health Car
2. IMA to create database on physicians
3. "Make AIDS Therapy affordable" - Physicians demand
4. Physicians Consider Self-Prescribing Ethical
5. Guide for physicians launched to help them identify alcohol disorders
6. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
7. Physicians Need To Treat Patients With Respect For Treatment To Be Effective
8. Resident Physicians Need More Preparations To Treat Patients From Different Cultures
9. Physicians To Discuss Ways To Save Premature Babies From RSV
10. Physicians should encourage US women to breastfeed
11. Conflict over Productivity Commission report on physicians referral
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... The ... supply chain professionals, will hold their first Northeast Regional AHVAP Meeting. For 2017, ... , “Increasingly, supply chain and value analysis professionals have a ‘seat at the ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... Conventional sodium testing methods are complicated and require expert user knowledge. In a ... analytical method dedicated to the simplified, yet highly accurate, determination of sodium. , ...
(Date:3/27/2017)... ... March 27, 2017 , ... From 1999 ... alone responsible for over 33,000 of the 52,404 drug-related deaths in 2015.(2) To ... 1512, which proposes a tax on prescription opioids to fund drug rehabilitation and ...
(Date:3/25/2017)... ... 25, 2017 , ... Getting earned media coverage meaningful for Garden Media Group's ... through the year, Garden Media aims to provide material helpful to clients’ goals and ... pitching client’s key messages to gain coveted media placements, Garden Media wows clients ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mediaplanet today announces distribution of ... current obstacles facing infection prevention and offer strategies for the health care community ... , The print component of “Fighting Infection” is distributed within the Friday, ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... BOSTON , March 27, 2017 ... pharmaceutical company and Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), ... commercialization of innovative therapies based upon tetracycline chemistry, ... sarecycline for the treatment of moderate to severe ... Sarecycline is a once-daily, oral, narrow spectrum tetracycline-derived ...
(Date:3/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that ... Bisaro as Impax,s President and Chief Executive Officer ... 27, 2017. Mr. Bisaro will succeed J. Kevin ... Chief Executive Officer since December of 2016. ... experience, Mr. Bisaro, 56, is an accomplished global business ...
(Date:3/27/2017)... March 27, 2017  PhaseRx, Inc. (NASDAQ: PZRX), ... inherited liver diseases in children, today reported financial ... ended December 31, 2016 and provided an update ... continued to make progress during the fourth quarter ... from our non-human primate safety study, and with our ...
Breaking Medicine Technology: